Testosterone Cypionate in Men 65 and Older: Transition to Adult Care

Why Age Changes Everything About Testosterone Cypionate Dosing

Testosterone cypionate behaves differently in a 70-year-old than in a 35-year-old. Hepatic clearance slows, lean muscle mass falls, sex hormone-binding globulin (SHBG) rises, and the hypothalamic-pituitary axis loses sensitivity. Each change shifts the dose-response curve and raises the risk of hematologic and cardiovascular side effects.

The Endocrine Society's 2018 clinical practice guideline states directly: "We suggest against starting testosterone therapy in patients with hematocrit >48%, untreated severe obstructive sleep apnea, uncontrolled heart failure, or a palpable prostate nodule." [1] That language applies to all adults but carries extra weight in men over 65, who carry a higher baseline burden of exactly those conditions.

The Pharmacokinetic Shifts That Matter Most

SHBG rises roughly 1 to 2% per year of age after 40. [2] Because testosterone cypionate raises total testosterone, but only the free fraction is biologically active, a man with elevated SHBG may show a normal total testosterone reading while still experiencing symptomatic hypogonadism. Clinicians transitioning geriatric patients to a new practice setting must recheck free testosterone or calculated free testosterone at the first visit, not just total testosterone.

Renal function also affects fluid balance in men receiving testosterone, and age-related decline in glomerular filtration rate can amplify the sodium-retaining properties of androgens. A baseline creatinine and eGFR at transition is reasonable practice, particularly if the patient has existing heart failure or stage 3+ chronic kidney disease. [3]

Starting Dose Rationale in Men 65 and Older

Standard adult dosing for testosterone cypionate runs 100 to 200 mg intramuscularly every 7 to 14 days. Geriatric-specific guidance from the Endocrine Society and clinical pharmacology data support starting at the lower end, typically 50 to 75 mg weekly or 100 mg every 14 days, and titrating upward only after confirming trough levels at weeks 6 to 8. [1]

The FDA-approved prescribing information for testosterone cypionate injection notes that "geriatric patients treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma" and advises caution. [4] That label language is not a contraindication, but it requires documented informed consent and a baseline PSA before any injection is given.

Diagnosing Hypogonadism Correctly Before the First Injection

Symptom scores alone do not justify treatment. Two separate fasting morning total testosterone measurements, drawn before 10 a.m. On different days, must both fall below 300 ng/dL before testosterone cypionate is appropriate. [1]

The T Trials (Testosterone Trials), a coordinated set of seven placebo-controlled trials in men 65 and older with testosterone <275 ng/dL, provide the strongest evidence base for clinical decision-making in this age group. [5] Across 790 participants, testosterone gel raised serum testosterone into the mid-normal range and improved sexual function scores, but benefits on physical function, vitality, and cognition were more modest or absent in some sub-trials.

Differentiating Primary from Secondary Hypogonadism

Older men more often show mixed or secondary hypogonadism, where the pituitary output of LH and FSH is blunted. A single elevated LH with low testosterone points toward primary testicular failure, while normal or low LH alongside low testosterone suggests secondary or functional causes, including obesity, sleep apnea, opioid use, or pituitary pathology.

At transition, the receiving clinician needs the original LH, FSH, prolactin, and morning testosterone values that triggered the diagnosis. Without those, restarting the diagnostic workup is safer than assuming the original diagnosis was complete.

Conditions That Must Be Excluded Before Transferring Care

The care transition checklist should confirm that the referring provider has excluded:

• Untreated obstructive sleep apnea (OSA). OSA worsens on testosterone and is present in roughly 40% of men over 65 with obesity. [6]
• Active or recent prostate cancer. Testosterone is contraindicated in known or suspected prostate cancer. [4]
• Hematocrit above 48% at the last measurement. [1]
• Uncontrolled heart failure with reduced ejection fraction.

If any of these conditions are undocumented or unresolved, the receiving clinician should pause injections and complete evaluation before resuming.

Cardiovascular Safety: What the Evidence Actually Shows

Cardiovascular risk from testosterone therapy in older men was a significant regulatory and clinical concern for years, driven by two small studies in 2010 and 2013 that showed increased adverse cardiac events. The evidence has since become more nuanced.

The TRAVERSE trial, a randomized, placebo-controlled trial in 5,204 men ages 45 to 80 with hypogonadism and elevated cardiovascular risk, found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a median 33-month follow-up. [7] The hazard ratio for MACE was 1.07 (95% CI 0.94 to 1.21), meeting the pre-specified non-inferiority margin.

What TRAVERSE Did and Did Not Show

TRAVERSE is reassuring but not entirely permissive. The trial excluded men with recent myocardial infarction or stroke within 6 months, so that population remains unstudied. The trial also showed a statistically higher rate of atrial fibrillation in the testosterone group (3.5% vs. 2.4%, P<0.05) and pulmonary embolism (0.9% vs. 0.5%). [7] Those findings matter for geriatric patients, who have baseline higher risks of both conditions.

For men 65 and older, the practical guidance is: discuss TRAVERSE findings explicitly during the transition visit, document that discussion, and maintain close follow-up rather than extending monitoring intervals based on younger-adult protocols.

Hematocrit Monitoring as a Cardiovascular Proxy

Polycythemia is the most common laboratory side effect of testosterone cypionate and carries direct cardiovascular risk through increased blood viscosity and thrombosis. Older men are more susceptible. A 2021 analysis of testosterone users in the Veterans Affairs database found that men over 65 had a hematocrit elevation rate approximately 2.4-fold higher than men under 50 on the same dose. [8]

Check hematocrit at baseline, at 3 months, at 6 months, and annually thereafter. Reduce the dose or extend the injection interval if hematocrit exceeds 50%. Hold entirely if it exceeds 54% and do not resume until hematocrit falls below 50% after phlebotomy or dose elimination. [1]

Prostate Monitoring Protocols for Older Men

The prostate concern with testosterone therapy is real but narrower than historically assumed. Testosterone does not appear to cause de novo prostate cancer, but it can stimulate growth of existing androgen-sensitive disease. Men over 65 have a higher prevalence of subclinical prostate cancer than younger men, making baseline and follow-up PSA essential.

The FDA prescribing information for testosterone cypionate requires a digital rectal exam and PSA before starting, with repeat PSA at 3 to 6 months after initiation. [4] Urology referral is appropriate if PSA rises more than 1.4 ng/mL above baseline within 12 months, or if baseline PSA exceeds 4.0 ng/mL. [1]

PSA Velocity as a Decision Tool

PSA velocity, defined as the rate of PSA rise per year, is a more sensitive trigger than absolute PSA alone. A velocity exceeding 0.4 ng/mL per year during testosterone therapy warrants urology evaluation even when absolute PSA remains below the traditional 4.0 ng/mL threshold. [9]

At care transition, request the full longitudinal PSA history, not just the most recent value. A pattern of rising PSA on a prior provider's records that was never acted upon becomes a patient-safety issue at the new practice.

Bone Density Benefits in the 65+ Population

Low testosterone is an independent risk factor for osteoporosis in older men. The T Trials bone sub-trial (N=202, mean age 72) found that testosterone treatment for 12 months increased lumbar spine BMD by 7.5% compared with 0.8% for placebo (P<0.001). [10] Femoral neck BMD improved by 4.1% vs. 0.7% for placebo.

Those are clinically meaningful numbers. A 70-year-old man with a DEXA T-score of minus 2.0 at the lumbar spine and confirmed hypogonadism has a reasonable evidence-based case for testosterone cypionate even when the cardiovascular risk picture is complex. The prescribing decision requires weighing those bone benefits against hematologic and cardiovascular risk on a patient-by-patient basis.

DEXA Scanning at Transition

Every geriatric patient transferring testosterone care should have a current DEXA scan or a scheduled one within 6 months of transfer. If the prior practice did not obtain baseline DEXA before starting treatment, the receiving clinician should order one at the first transition visit so that future changes can be measured against a known starting point.

The National Osteoporosis Foundation recommends DEXA for all men age 70 and older, and for men 50 to 69 with risk factors including hypogonadism. [11]

Structuring the Transition Visit

A geriatric patient transferring testosterone care needs more than a refill. The first visit with a new prescriber should follow a structured review before any new prescription is written.

The HealthRX Geriatric Testosterone Transition Framework covers five domains that every receiving clinician should address at the first visit:

1. Diagnosis validity. Were two separate morning testosterone levels drawn? Were secondary causes excluded? Is the LH/FSH pattern consistent with the stated diagnosis?

2. Current dose and response. What is the exact dose, injection interval, and injection site? What are the most recent trough and peak testosterone values? Has the patient self-adjusted dose or frequency?

3. Side-effect burden. Hematocrit trend over the past 12 months, current PSA and velocity, any new cardiac symptoms, sleep study results, lower urinary tract symptoms.

4. Comorbidity update. New diagnoses since the last testosterone review, any new medications that interact with androgens (notably anticoagulants, corticosteroids, insulin).

5. Patient goals. What symptoms are being treated? Has the patient noticed improvement? Are expectations aligned with what the evidence supports for his age group?

Required Records at Transfer

The receiving clinician should request these documents before or at the first visit:

• All serum testosterone values (total and free) from the past 24 months with draw times
• Hematocrit and hemoglobin values at each monitoring visit
• PSA values with dates
• LH, FSH, and prolactin from the original diagnostic workup
• Most recent DEXA report
• Any sleep study or sleep apnea diagnosis and treatment records
• The specific product name, lot source (compounded vs. Brand), concentration, and injection technique used

Compounded testosterone cypionate varies in concentration (commonly 100 mg/mL, 200 mg/mL, or 250 mg/mL). A patient transitioning from a compounding pharmacy to a commercial product, or vice versa, is at risk for dosing errors if concentration is not explicitly reconciled. [4]

Drug Interactions and Polypharmacy in Geriatric Patients

Men 65 and older take an average of 4.5 prescription medications. Testosterone cypionate interacts with several drug classes common in this demographic.

Oral anticoagulants, particularly warfarin, have their INR elevated by testosterone, sometimes substantially. The FDA label warns that patients on warfarin require more frequent INR monitoring after any dose change in testosterone. [4] Direct oral anticoagulants (DOACs) are less well studied in combination with testosterone, but clinicians should monitor for unexpected bleeding or bruising.

Insulin sensitivity improves with testosterone therapy in men with type 2 diabetes, which can cause hypoglycemia if insulin or sulfonylurea doses are not adjusted downward. [12] This is a particular concern at transition, when a new prescriber may not know the patient's baseline glycemic control pattern.

Corticosteroids and testosterone together can increase fluid retention, raising the risk of edema and decompensation in men with borderline cardiac function.

Medications That Lower Testosterone

Several drugs commonly prescribed to older men suppress endogenous testosterone production or block androgen action and are worth reviewing at the transition visit:

• Opioids. Chronic opioid therapy suppresses LH and FSH, causing secondary hypogonadism. A patient on long-term opioids may not be a candidate for testosterone unless the opioid therapy is expected to continue indefinitely and symptomatic hypogonadism is confirmed.
• Glucocorticoids. Chronic prednisone or equivalent suppresses the HPG axis.
• Ketoconazole and other azole antifungals. These inhibit testosterone synthesis.
• 5-alpha reductase inhibitors (finasteride, dutasteride). These do not lower testosterone but block conversion to DHT, altering the clinical response to exogenous testosterone.

Injection Technique and Patient Safety in Older Adults

Testosterone cypionate is an oily intramuscular injection. Older adults face practical barriers that younger patients do not: reduced grip strength, impaired vision, needle-phobia compounded by polypharmacy injection fatigue (insulin, enoxaparin), and muscle atrophy that changes the safety of standard injection sites.

The ventrogluteal site is preferred over the dorsogluteal site in older adults because it avoids the sciatic nerve and contains consistent muscle depth even in patients with low body mass. [13] The vastus lateralis (outer thigh) is a viable self-injection site for patients with adequate hand strength and range of motion.

At transfer, the receiving clinician or nurse should directly observe injection technique if the patient self-injects, rather than assuming prior training was adequate or current technique is safe. Needle length should be confirmed based on current body composition, not historical weight.

Monitoring Schedule After Transfer Is Established

Once the transition review is complete and any dose adjustments are made, the monitoring schedule for a stable geriatric patient on testosterone cypionate follows this structure based on Endocrine Society guidelines [1]:

• At 3 months post-transfer: Total testosterone (trough, drawn just before next injection), hematocrit, PSA, blood pressure, symptom review.
• At 6 months post-transfer: Repeat all 3-month labs, add free testosterone if SHBG was elevated at baseline, review any new symptoms including lower urinary tract symptoms, mood changes, or sleep disruption.
• Annually: All of the above, plus DEXA if not done in the prior 2 years, fasting lipid panel, and a formal cardiovascular risk recalculation using the Pooled Cohort Equations.

A patient who is genuinely stable on a fixed dose with documented normal hematocrit and PSA trend over 24 months can move to 6-month monitoring intervals, but annual DEXA and cardiovascular review should not be compressed further in men over 65.